A promising molecule can survive a bad metaphor. A young biotech usually cannot. SCIENT built its business around the awkward, consequential work of making complicated science understandable before the next investor meeting, clinical milestone, or corporate turning point.
A New Jersey agency found a business in the awkward distance between a scientific result and a human reaction. Its product is not publicity so much as translation - with enough regulatory discipline to survive the trip.